RecruitingNot ApplicableNCT05200351

Equine-assisted Therapy for Therapy-resistant Adolescents With Autism Spectrum Disorders, a Replicated AB-design


Sponsor

Karakter Kinder- en Jeugdpsychiatrie

Enrollment

35 participants

Start Date

Feb 14, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to assess the (cost)effectivity of Equine assisted Therapy in adolescents with Autism Spectrum disorders.


Eligibility

Min Age: 11 YearsMax Age: 18 Years

Inclusion Criteria4

  • between 11-18 years old;
  • a clinical diagnosis of autism spectrum disorders according the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM 5) as diagnosed by a Beroepen in de Individuele Gezondheidszorg (BIG) registered healthcare professional;
  • insufficient emotion regulation after regular therapy for at least 1,5 years as indicated by a score above clinical cut-off (T-score = 65) on the EDI;
  • comorbidities are allowed except for those interfering with safety.

Exclusion Criteria9

  • unable to respond to questions (parents or adolescents);
  • no access to an Internet connection;
  • insufficient mastery of Dutch language in parents or adolescents;
  • physically incapable to work with the horses;
  • unstable medication use;
  • total intelligence quotient (IQ) equal to or below 80 on the Wechsler Intelligence Scale for Children (WISC-III-R or WISC-V);
  • allergic or phobic to horses;
  • insufficient regulation to safely handle the horses;
  • therapy with horses within the last two years.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALEquine assisted Therapy (EAT)

15 sessions of EAT will be given. Activities will be with or in the presence of the horse. There will be no horseriding.


Locations(3)

Karakter

Ede, Gelderland, Netherlands

Horses & Co

Heerjansdam, Netherlands

De Gagelhoeve

Mill, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05200351


Related Trials